Anuh Pharma Ltd, incorporated on February 19, 1960, is a prominent manufacturer of Active Pharmaceutical Ingredients (APIs) and bulk drugs in India. The company, a part of the SK Group, specializes in antibiotics, erythromycin salts, chloramphenicol, and other chemicals. It is recognized as a medium-sized player within the API/bulk drugs industry.
APL is a leading manufacturer of Macrolides and Anti-TB products in India, and also holds a significant position in Anti-bacterials, Anti-malarial, Anti-hypertension, and Corticosteroids segments. Its product portfolio includes critical compounds such as erythromycin and its salts, higher macrolides like azithromycin, roxithromycin, pyrazinamide, and chloramphenicol.
Anuh Pharma Ltd boasts strong market leadership in several specialized pharmaceutical ingredients. The company claims to be:
* The largest producer of erythromycin salts in India, and among the top five globally.
* The largest producer of pyrazinamide in the world.
This dominant position provides Anuh Pharma with a significant competitive advantage in the API industry. The company maintains high-quality production standards and regulatory compliance, with its manufacturing operations at Tarapur in Maharashtra built and operated according to current Good Manufacturing Practices (cGMP). This strategic positioning enables the company to effectively serve its existing and potential markets.
The company's diverse product portfolio spans several therapeutic categories:
* Macrolides: Erythromycin, Erythromycin Ethyl Succinate, Erythromycin Stearate, Erythromycin Estolate, Erythromycin Propionate, Erythromycin Phosphate, Erythromycin 11,12 Carbonate, and Azithromycin.
* Anti-TB Products: Pyrazinamide and Isoniazid.
* Anti-Malarial Products: Sulfadoxine and Pyrimethamine.
* Other Segments: Anti-Bacterials, Anti-Hypertension, Expectorant, and Corticosteroids.
Anuh Pharma Ltd is a recognized export house with a substantial global footprint. The company exports its products to a wide range of countries including Mexico, Brazil, Iran, Bangladesh, Colombia, Germany, various African nations, Singapore, and more. APL has established marketing partnerships with 350 customers across over 57 countries, including key markets in Europe, Mexico, and South Africa.
In 2010, the company achieved significant international recognition with approvals from the European Directorate for the Quality of Medicines and Healthcare (EDQM) for three key products: Erythromycin E.P., Pyrazinamide, and Clobetasol Propionate. These approvals opened up substantial opportunities for the company to market and sell its products in European countries for local consumption.
As of May 23, 2025:
* Market Capitalization: ₹1,039.27 Crore
* Promoter Holding: 69.91% (as of Mar 2025)
* Latest PE Ratio: 20.65
* Latest PB Ratio: 0.29
* 52-Week High Share Price: ₹245.70
* 52-Week Low Share Price: ₹148.50
For the Financial Year Ended March 2025:
* Net Profit: Declined 21.16% to ₹47.35 crore (compared to ₹60.06 crore in FY2024).
* Sales: Rose 2.24% to ₹661.51 crore (compared to ₹647.00 crore in FY2024).
For Q4 FY2025 (Quarter Ended March 2025):
* Net Profit: Declined 18.88% to ₹12.46 crore (compared to ₹15.36 crore in Q4 FY2024).
Anuh Pharma Ltd operates its primary manufacturing facilities at Tarapur in Maharashtra. These facilities are built according to current Good Manufacturing Practices (cGMP) standards, ensuring high-quality production and strict regulatory compliance.
Recent investments in modern facilities and the addition of new plants have significantly increased the company's installed capacity:
* Antibiotics: Capacity increased from 400,000 kg to 600,000 kg per annum.
* Other Products: Capacity increased up to 150 MT per annum.
The company has also received plant approvals from several multinational corporations, further validating its manufacturing prowess and quality standards.
The business headquarters of Anuh Pharma Ltd are located in Mumbai, the commercial capital of India. Promoter holding in the company has remained stable at 69.91% as of March 2025, from September 2024, indicating consistent confidence from the core management.
* Dividend: Final Dividend of ₹1.50 (30%) per equity share of Face Value of ₹5 each for the Financial Year ended March 31, 2025.
* Bonus Issue: The company has also announced a bonus issue of 1:1, meaning shareholders will receive one additional share for every share held.
Anuh Pharma Ltd represents a well-established player in the Indian pharmaceutical API industry with strong market positions in specific therapeutic segments, global reach, and modern manufacturing capabilities. The company's focus on quality, regulatory compliance, and strategic positioning in high-value pharmaceutical ingredients makes it a significant participant in India's growing pharmaceutical sector.
```
